Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects
Authors:
- 1 May 2011
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 31 (5) , 325-335
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transportJournal of Lipid Research, 2010
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular EventsNew England Journal of Medicine, 2007
- Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialThe Lancet, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- Efficacy and safety of high-density lipoprotein cholesterol-increasing compoundsJACC, 2005
- Cholesteryl Ester Transfer ProteinArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transportAtherosclerosis, 1996
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977